Residents with high cholesterol have a new choice. On August 27, the U.S. Food and Drug Administration announced approval of a Repatha injection for patients who cannot reduce their low-density ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Most Medicare Part D and Advantage plans cover Repatha injections. Read about the cost of Repatha after paying the deductible, generic alternatives, and more.

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase ...

Amgen announced the submission of an application to the Food and Drug Administration (FDA) seeking approval of a single-injection option for the monthly administration of the 420mg dose of Repatha ...

U.S. regulators on Thursday approved Repatha, the second injectable drug of its kind designed for certain patients with stubbornly high cholesterol which puts them at risk of heart disease. Repatha… ...

The FDA approved Amgen’s cholesterol-lowering drug on Thursday, teeing up a rivalry with a similar treatment that was approved just weeks earlier.

As the first PCSK9 inhibitor to make it to market, evolocumab is approved in a wide array of patients, including the statin intolerant and those unable to get to goal with maximally tolerated statin.